NGNicole R. Guinn

Nicole R. Guinn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicole R. Guinn has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early Use of Cryoprecipitate Versus Plasma and Clinical Outcomes in Major Spine Surgery

    by Aparna Depuru, Jong Ok La, Miriam M. Treggiari, Nicole R. Guinn

    Background/Objectives: Major spine surgery often leads to significant blood loss and coagulopathy, necessitating blood product transfusion. Cryoprecipitate and plasma are two blood products commonly used to manage coagulopathy, but outcomes associated with their use in spine surgery remain unclear. Methods: This retrospective cohort study included adult patients undergoing major spine surgery from 2015 to 2022 within a single health system. Included patients received at least one unit of packed red blood cells (PRBCs) followed by either cryoprecipitate or plasma to investigate the treatment of coagulopathy after blood loss. Study endpoints included hospital length of stay (H-LOS), ICU length of stay (ICU-LOS), discharge disposition, one-year mortality, and total blood products transfused up to postoperative day (POD) 2. Multivariable linear and logistic regression was used to estimate associations between the use of cryoprecipitate or plasma and outcomes. Results: Of 189 patients meeting inclusion criteria, 120 received cryoprecipitate, and 69 received plasma as the first product after PRBCs. In the univariable analysis, the cryoprecipitate group had lower 1-year mortality (5.0% vs. 14.5%; [95% CI]: 0.31 [0.10, 0.88], p = 0.0031) and a shorter ICU-LOS (46 vs. 74 h; [95% CI]: 0.73 [0.53, 1.00], p = 0.048). However, despite a trend favoring the cryoprecipitate group, there were no differences between the cryoprecipitate and plasma groups in the multivariable model for H-LOS (adjusted geometric mean ratio [95% CI]: 0.84 [0.68, 1.04], p = 0.109), ICU-LOS (adjusted geometric mean ratio [95% CI]: 0.72 [0.50, 1.04], p = 0.078), one-year mortality (adjusted OR [95% CI]: 0.49 [0.13, 1.88], p = 0.288), or total blood products transfused up to POD2 (adjusted mean difference [95% CI]: −1 unit [−2, 1], p = 0.253). Compared with plasma, patients in the cryoprecipitate group were more likely to be discharged to home independently versus disposition to other facility or needing assistance (adjusted OR 0.41 [95% CI]: 0.16, 0.97, p = 0.049). Conclusions: Use of cryoprecipitate was associated with higher odds of home discharge, while other outcomes were similar between the two groups once adjusting for potential confounders. Further research is needed to better appreciate the clinical impact of the choice of blood products to treat coagulopathy in the setting of bleeding in major spine surgery.


  • How do we improve massive transfusion protocol adherence among anesthesia providers?

    by Ana Julia H. Parks, Susan G. Silva, Jessica L. Poisson, Virginia C. Simmons, Nicole R. Guinn, Adam M. Flowe, Valerie K. Sabol

    Background: Previous studies have called for the implementation of provider reeducation efforts to improve massive transfusion protocol adherence.Objective: This quality improvement project implemented an educational module designed to increase anesthesia provider adherence to the hospital's massive transfusion protocol during the intraoperative massive transfusion of trauma patients. It also aimed to increase survival rates for trauma patients in the operating room for whom a massive transfusion protocol had been activated.Methods: An educational intervention was developed and disseminated to anesthesia providers. The intervention consisted of a PowerPoint presentation, an expert question‐and‐answer session, and the distribution of a badge card. Provider knowledge of and confidence in utilizing the protocol was evaluated before and after the intervention, while provider adherence to the packed red blood cell:fresh frozen plasma and packed red blood cell:platelet ratios outlined in the massive transfusion protocol and patient survival were assessed for 4 months pre‐ and post‐implementation of the intervention.Results: The knowledge test scores of the 18 anesthesia providers participating in the education significantly improved after the intervention (p = .0005). Provider confidence in utilizing the massive transfusion protocol also substantially improved. Provider adherence to the massive transfusion protocol was determined for 20 trauma cases (11 pre‐and 9 post‐intervention). Although the adherence to the packed red blood cell:fresh frozen plasma ratio and packed red blood cell:platelet ratios improved, patient survival rates did not increase.Conclusion: Project findings suggest that provider massive transfusion protocol reeducation efforts improve provider protocol knowledge, confidence, and adherence.


  • Open Access

    Spinal Anesthesia Results in Lower Costs Compared to General Anesthesia for Patients Undergoing Lumbar Fusion—A Matched Cohort Study

    by Favour C. Ononogbu-Uche, Abdullah Wael Saleh, Felix Toussaint, Taylor Wallace, Joshua Woo, Matthew T. Morris, Christopher I. Shaffrey, William M. Bullock, Nicole R. Guinn, Muhammad M. Abd-El-Barr

    Background/Objectives: Degenerative lumbar spine disease (DLSD) is increasingly managed with minimally invasive surgery (MIS) and evolving anesthesia methods. While general anesthesia (GA) remains standard, spinal anesthesia (SA) may offer faster recovery and fewer side effects. This study compares the clinical and economic outcomes of GA versus SA in transforaminal lumbar interbody fusion (TLIF). Methods: A retrospective review of 18 TLIF patients (2018–2022) was performed, with 9 patients in each cohort. Patients were matched by demographics and procedure type. Data collected included operative time, blood loss, complications, postoperative opioid utilization, and 30-day readmissions. Costs were analyzed in categories: anesthesia, implants, inpatient care, operating room (OR) supplies, OR time, and PACU fees, using Wilcoxon Rank T-tests and Pearson Chi-Squared tests. Results: Clinical outcomes such as blood loss, and operative time were similar between groups. However, SA patients had significantly shorter LOS compared to GA (SA: 12 h vs. GA: 84 h, % difference: −150%, p = 0.04). Additionally, SA patients had lower total direct costs ($27,881.85 vs. $35,669.01; p = 0.027). Significant cost reductions with SA were noted in OR supplies/medications ($7367.93 vs. $10,879.46; p = 0.039) and inpatient costs ($621.65 vs. $3092.66; p = 0.027). Within these categories, reductions were observed for intravenous solutions, sedatives/anesthetics, pressure management, labs, imaging, evaluations, hospital care, and medications. Although costs for implants, anesthesia care, OR time, and PACU fees were lower with SA, these differences did not reach statistical significance. Conclusions: In TLIF for DLSD, SA provides significant economic advantages over GA while yielding comparable clinical outcomes. These results support SA as a cost-effective alternative, warranting further prospective studies to confirm these findings.


  • In Response

    by Nicole R. Guinn, Elliott Bennett-Guerreo

  • Perioperative Quality Initiative and Enhanced Recovery After Surgery-Cardiac Society Consensus Statement on the Management of Preoperative Anemia and Iron Deficiency in Adult Cardiac Surgery Patients

    by Nicole R. Guinn, Jonathon Schwartz, Rakesh C. Arora, Vicki Morton-Bailey, Solomon Aronson, Charles Scott Brudney, Elliott Bennett-Guerrero, on behalf of the Perioperative Quality Initiative (POQI-8) and the Enhanced Recovery After Surgery-Cardiac Society (ERAS-C) Investigators

    Preoperative anemia is common in patients presenting for cardiac surgery, with a prevalence of approximately 1 in 4, and has been associated with worse outcomes including increased risk of blood transfusion, kidney injury, stroke, infection, and death. Iron deficiency, a major cause of anemia, has also been shown to have an association with worse outcomes in patients undergoing cardiac surgery, even in the absence of anemia. Although recent guidelines have supported diagnosing and treating anemia and iron deficiency before elective surgery, details on when and how to screen and treat remain unclear. The Eighth Perioperative Quality Initiative (POQI 8) consensus conference, in conjunction with the Enhanced Recovery after Surgery-Cardiac Surgery Society, brought together an international, multidisciplinary team of experts to review and evaluate the literature on screening, diagnosing, and managing preoperative anemia and iron deficiency in patients undergoing cardiac surgery, and to provide evidence-based recommendations in accordance with Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria for evaluating biomedical literature.


  • Treatment through a preoperative anemia clinic is associated with a reduction in perioperative red blood cell transfusion in patients undergoing orthopedic and gynecologic surgery

    by Nicole R. Guinn, Matt Fuller, Sutton Murray, Solomon Aronson, the Duke Perioperative Enhancement Team (POET)

    Background: Preoperative anemia is associated with increased morbidity, mortality, and risk of transfusion. Treatment through a preoperative anemia clinic (PAC) may improve outcomes.Study Design and Methods: Adult patients undergoing elective orthopedic and gynecologic surgery with preoperative anemia were identified and referred for hemoglobin optimization with iron and/or erythropoietin from a single‐site academic health center. Treated patients were propensity matched to untreated controls and compared on outcomes of erythrocyte transfusion, length of stay (LOS), and readmission. Changes in hemoglobin relative to treatment time before surgery were also measured in the treated cohort.Results: One thousand three hundred thirty‐two patients were evaluated between July 2015 and March 2021, of which 161 underwent optimization through the PAC. After propensity matching, 127 (98 orthopedic and 29 gynecology) PAC‐treated patients were compared to 127 (98 orthopedic and 29 gynecology) control patients who did not undergo treatment. The primary outcome of perioperative transfusion was significantly lower in treated patients compared with matched controls (12.60% vs. 26.77%, p = .005). A lower LOS was demonstrated in the gynecologic PAC subgroup (2.2 [1.5, 2.4] vs. 3.1 [2.2, 3.4], p = .002). Each day of treatment time before surgery was associated with an increase of 0.040 g/dL hemoglobin (p < .001) until 65 days, after which further time did not increase hemoglobin.Conclusion: Treatment through a preoperative anemia clinic is associated with a reduction in perioperative transfusion and possible reduction in LOS and readmission compared with matched controls. Additionally, treatment time before surgery is correlated with a greater increase in hemoglobin up until 2 months prior to surgery.


  • Perioperative Management of Patients for Whom Transfusion Is Not an Option

    by Nicole R. Guinn, Linda M. S. Resar, Steven M. Frank


  • Open Access

    Surgical management of ovarian carcinosarcoma with inferior vena cava extension into the right atrium

    by Akeel M Merchant, Mark D Friedland, Marcus A Behrens, Adam R Williams, Andrew Berchuck, Nicole R Guinn

    Gynecological carcinosarcomas are aggressive tumors with rare occurrence and high rates of metastases. We present the case of a 49-year-old woman with vaginal bleeding and abdominal distension who was found to have a large ovarian carcinosarcoma invading the gonadal vein and inferior vena cava (IVC) and extending into right atrium (RA). She underwent gynecologic tumor resection, IVC cavotomy and en bloc resection of tumor/thrombus through the RA. Use of intraoperative transesophageal echocardiography helped assess extent and mobility of mass in the RA to guide surgical approach. This case posed unique challenges with regard to management of induction, hemodynamics and coagulopathy.

  • The need for an artificial oxygen carrier for disasters and pandemics, including COVID‐19

    by Richard B. Weiskopf, Elon Glassberg, Nicole R. Guinn, Michael F. M. James, Paul M. Ness, Anthony E. Pusateri